Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization

RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology’s 70th Annual Scientific Session (ACC.21) and simultaneously published in the Journal of the American College of Cardiology. PAD is a chronic circulatory condition which causes blood vessels to narrow, thereby reducing blood flow to the limbs, most often the legs.1 An estimated 20 million Americans are living with PAD, but only 8.5 million are currently diagnosed.2 While usually starting as asymptomatic, PAD symptoms can progress to severe and require revascularization to avoid amputation. “Even years after revascularization, patients with...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

More News: Allergy & Immunology | Anesthesia | Anesthesiology | Antiphospholipid Syndrome | Aspirin | Atrial Fibrillation | Babies | Babies Heart Conditions | Back Pain | Bleeding | Brain | Breastfed | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chronic Pain | Clinical Trials | Clopidogrel | Complementary Medicine | Cough | Coumadin | Dentistry | Emergency Medicine | Epistaxis (Nosebleeds) | Food and Drug Administration (FDA) | Grants | Headache | Health Management | Heart | Heart Attack | Heart Transplant | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Herbs | Hospitals | Hughes Syndrome | Incontinence | Ischemic Stroke | Kidney Transplant | Legislation | Liver | Liver Transplant | Lung Transplant | Men | Milk | Neurology | New Drug Applications | Pain | Peripheral Vascular Disease (PVD) | Pharmaceuticals | Plavix | Pregnancy | Profits and Losses | Sodium | Stroke | Study | Urology & Nephrology | Vitamins | Warfarin | Warnings